Reich, Kristian, et al. “Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Active Psoriatic Arthritis and Moderate-to-Severe Psoriasis: 52-Week Results from the Randomised SPIRIT-H2H Trial”. Dermatology Practical & Conceptual, vol. 12, no. 2, May 2022, p. e2022104, https://doi.org/10.5826/dpc.1202a104.